Shensongyangxin Capsule in the Treatment of Sinus Bradycardia With Premature Ventricular Contractions

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 330 participants.

Also called NCT01750775

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 330 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT01750775
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT01750775. Randomized; triple masking; primary purpose treatment. Start 2012-08 (registry gives no type); primary completion 2013-09 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Shensongyangxin Capsule in the Treatment of Sinus Bradycardia With Premature Ventricular Contractions
Acronym
SS-SBVPT
Condition
Premature Ventricular Contraction
Intervention (Drug)
Shensong Yangxin capsule
Intervention (Drug)
placebo Capsule
Lead sponsor
kejiang Cao (class: other)
Collaborator
Chinese Academy of Medical Sciences, Fuwai Hospital (class: other)
Collaborator
Third Military Medical University (class: other)

Record details

Record id
cardio:ct-nct01750775
Content hash
95b5e4ffdf83fcf71ef176b6af295438be2135de7d548afb111b0226c439e5b2